Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CellaVision AB ( (SE:CEVI) ) is now available.
CellaVision has appointed Monica Jönsson as the Interim CFO, succeeding Magnus Blixt. Monica brings extensive experience from her previous roles, including her position as Group CFO at Perstorp Group. The company is in the process of recruiting a permanent CFO. This leadership change is expected to bring valuable expertise to CellaVision, potentially impacting its operations and market positioning positively.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK201.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision is a global medical technology company specializing in developing and selling advanced systems for routine analysis of blood and other body fluids in healthcare services. Their products are crucial for accurate disease diagnosis, replacing manual laboratory work and enhancing workflow efficiency. The company operates in over 40 countries, with a strong focus on sample preparation, image analysis, artificial intelligence, and automated microscopy. CellaVision is headquartered in Lund, Sweden, and is listed on the Nasdaq Stockholm Mid Cap list.
Average Trading Volume: 18,015
Technical Sentiment Signal: Sell
Current Market Cap: SEK4.15B
For detailed information about CEVI stock, go to TipRanks’ Stock Analysis page.